Wegovy vs Mounjaro Ireland | GLP-1 Weight Loss Comparison 2026
GLP-1 Specialist · Naas, Co. Kildare

Wegovy vs Mounjaro
Which GLP-1 Is Right for You?

Both Wegovy and Mounjaro are clinically proven weight-loss injections available on private prescription in Ireland. Our consultant specialist explains the differences.

The Two Leading Weight-Loss Injections

Wegovy (semaglutide) and Mounjaro (tirzepatide) are both injectable GLP-1 receptor agonists approved for chronic weight management and available on private prescription in Ireland.

FeatureWegovy (Semaglutide)Mounjaro (Tirzepatide)
MechanismGLP-1 receptor agonistGLP-1 + GIP dual receptor agonist
Average weight loss~15% body weight (STEP trials)~20-22% body weight (SURMOUNT trials)
Injection frequencyOnce weeklyOnce weekly
Cardiovascular benefitProven (SELECT trial) - 20% CVD risk reductionPromising - SURPASS-CVOT awaited
Side effectsNausea, vomiting, diarrhoea, constipationNausea, diarrhoea, vomiting, constipation
Starting dose0.25mg/week, escalate to 2.4mg/week2.5mg/week, escalate to 15mg/week

The Established Option

The SELECT cardiovascular outcome trial (2023, NEJM) showed a 20% reduction in major cardiovascular events in people with obesity who had pre-existing heart disease. Wegovy is the first anti-obesity drug proven to reduce heart attacks and strokes.

  • Extensive long-term safety data (5+ years)
  • Proven cardiovascular benefit (SELECT trial)
  • Preferred if you have existing heart disease
  • Well-tolerated at lower doses

The More Powerful Option

Tirzepatide (Mounjaro) acts on two hormone receptors - GLP-1 and GIP. The SURMOUNT-1 trial showed average weight loss of 20.9% at the highest dose. Excellent for patients with type 2 diabetes or insulin resistance.

  • Greater average weight loss (~20-22%)
  • Dual action on GLP-1 and GIP receptors
  • Superior blood glucose improvement (T2DM)
  • Excellent for insulin resistance and PCOS

Common Questions

Can I get Wegovy or Mounjaro without a GP referral in Ireland?

Yes. At Naas Cardiology & Endocrinology Clinic, Dr Kazmi accepts self-referrals. A full medical history review including blood tests is required before prescribing.

How long to see results?

Most patients notice appetite reduction within 1-2 weeks. Meaningful weight loss (5-10%) typically occurs within 3 months. Maximum effect at 12-16 months on maintenance dose.

Can I switch from one to the other?

Yes. Some patients switch from Wegovy to Mounjaro if they plateau, or vice versa. This transition is managed by your consultant with an appropriate washout period if required.

Book a GLP-1 Specialist Consultation

Dr Kazmi, Consultant Endocrinologist (IMC 213626). Sunday appointments in Naas, Co. Kildare.

Book Appointment Learn About GLP-1 Therapy